<DOC>
	<DOC>NCT01454531</DOC>
	<brief_summary>The purpose of this study is to assess the tolerability of AVANZ.</brief_summary>
	<brief_title>An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy</brief_title>
	<detailed_description>To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.</detailed_description>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>History of grass pollen rhinoconjunctivitis Positive SPT to Phleum pratense Positive specific IgE against Phleum pratense Uncontrolled severe asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>